[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586769":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":20,"responsibleParty":21,"collaborators":20,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":20,"studyType":38,"phases":39,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":48,"whyStopped":20,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":20},{"fullName":5,"class":6},"University of Cologne","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET\u002FCT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively.",[13],"Drug: BrECADD",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","BrECADD","Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone",[9],null,{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Prof. Dr. Peter Borchmann","Prof.","100586769","phase-2-phase-ii-trial-of-brecadd-in-hiv-positive-patients-with-advanced-stage-classical-hodgkin-lymphoma-100586769",false,"NCT06919679","Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma","BASTION","Inclusion Criteria:\n\n* Histologically confirmed first diagnosis of cHL\n* Advanced-stage disease: stage IIB with large mediastinal mass and\u002For extranodal lesions or stage III or IV\n* No previous treatment for HL with the exception of steroid prephase\n* Confirmed HIV infection with CD4 counts ≥ 150\u002FμL at registration or \\> 250\u002FμL at any time within 8 months prior to HL diagnosis\n* Continuation of antiretroviral treatment (ART) \u002F Initiation of ART in patients who are ART-naive\n* Age: 18-60 years\n\nExclusion Criteria:\n\n* Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma\n* Multi-drug resistant HIV infection or concurrent AIDS-defining conditions\n* Pregnancy or breastfeeding","ALL","18 Years","60 Years",{"count":36,"type":37},35,"ESTIMATED","INTERVENTIONAL",[40],"PHASE2","Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET\u002FCT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.",[43],"Hodgkin Lymphoma (Category)",[45,46,47],"advanced stage","HIV positive","Brentuximab Vedotin","NOT_YET_RECRUITING","2025-04-02",{"date":51,"type":52},"2025-04-09","ACTUAL",{"date":54,"type":37},"2025-08",{"date":56,"type":37},"2030-01",{"name":5,"class":6}]